drugset / Press release
Almirall and Forest announce positive results from the ATTAIN Phase III study of aclidinium bromide and the Phase IIb studies with the fixed dose combination with formoterol in moderate to severe COPD patients
2011-01-04 · Almirall, S.A. · original almirall.com ↗
·ATTAIN results confirm clinically significant bronchodilation and improvement of symptoms in COPD patients treated with aclidinium bromide twice daily (BID)
The release as fetched from its publisher. almirall.com ↗